“…PRMT1, a type I enzyme, is the predominant isoform in mammalian cells accounting for ~85% of total protein arginine methylation (Tang et al, 2000 ). Knockout of PRMT1 in mice results in embryo lethality (Pawlak et al, 2000 ) while altered PRMT1 protein expression has been reported in various types of cancer, including lung, breast, bladder, and pancreatic cancers (Feng et al, 2023 ; Filipović et al, 2019 ; He et al, 2020 ; Song et al, 2020 ; Wang et al, 2019 ; Yoshimatsu et al, 2011 ), as well as in idiopathic pulmonary fibroses (Lambers et al, 2019 ; Zakrzewicz et al, 2014 ; Zakrzewicz et al, 2015 ) and asthma (Park et al, 2021 ; Sun et al, 2017 ). The catalytic core of PRMT1 contains a Rossman fold that binds the cofactor AdoMet, a beta‐barrel that is thought to be involved in substrate binding (Schapira & Ferreira de Freitas, 2014 ), and a dimerization arm.…”